Alpha Tau Medical Ltd. reported a net loss of $68.8 million for the six months ended June 30, 2026, driven by increased R&D expenses and significant non-cash warrant remeasurement charges. The company secured a strategic collaboration with Tolmar International Ltd., granting exclusive U.S. commercialization rights to Alpha DaRT for prostate cancer in exchange for a $15 million upfront payment and a $20 million private placement of equity securities at $11.99 per share. Concurrently, the firm received Japanese regulatory approval (shonin) for head and neck cancer and completed enrollment in its U.S. pivotal ReSTART trial for cutaneous squamous cell carcinoma. The company maintains a cash position of approximately $104.8 million to fund operations through 2028. Alpha Tau Medical Ltd. is an Israeli clinical-stage oncology therapeutics company developing Alpha DaRT technology for localized radiation therapy in solid tumors.